Patients
allergies
CIN 2, INVASIVE CANCER, PATHOLOGY, ALLERGIES
Patients with pathologically determined CIN 2 or 3 who were positive for HPV-16 by HPV genotyping using exfoliated cervical cells were eligible for enrollment. A central review for pathological diagnosis was set up to exclude bias in pathology diagnosis between the 4 centers and among pathologists. Two pathologists specializing in gynecologic oncology independently observed whole slide images obtained from biopsies taken under colposcopy by gynecologic oncologists and determined the pathological diagnosis by consensus. Registration was based on the results of the central pathological review. HPV typing was performed using a commercial testing company; positive for HPV-16 only or positive for HPV-16 and other types were differentiated and recorded. Patients aged 20-45 years were included. Pregnant or postpartum women were excluded. Patients with allergies to lactic acid beverages or dairy products were excluded. Patients with findings suggestive of invasive cancer were also excluded. A complete list of the inclusion and exclusion criteria is provided in the Clinical Trial Protocol (